JP5734654B2 - Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 - Google Patents

Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 Download PDF

Info

Publication number
JP5734654B2
JP5734654B2 JP2010525102A JP2010525102A JP5734654B2 JP 5734654 B2 JP5734654 B2 JP 5734654B2 JP 2010525102 A JP2010525102 A JP 2010525102A JP 2010525102 A JP2010525102 A JP 2010525102A JP 5734654 B2 JP5734654 B2 JP 5734654B2
Authority
JP
Japan
Prior art keywords
tert
butyl
dioxotetrahydropyrimidin
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010525102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539186A (ja
JP2010539186A5 (enExample
Inventor
ワグナー，ロルフ
テユフアノ，マイケル・デイー
スチユワート，ケント・デイー
ロツクウエイ，トツド・ダブリユ
ランドルフ，ジヨン・テイー
プラツト，ジヨン・ケイ
モツター，クリストフアー・イー
マーリング，クラレンス・ジエイ
ロングネツカー，ケントン・エル
リウ，ヤーヤー
リウ，ターチユン
クリユーガー，アラン・シー
ケイテイ，ウオーレン・エム
ハツチンソン，ダグラス・ケイ
ホワン，ペギー・ピー
フレンテ，チヤールズ・エイ
ドナー，パメラ・エル
デイゴーイ，デイビツド・エイ
ベテベナー，デイビツド・エイ
バーンズ，デイビツド・エム
チエン，シヨワン
フランチエク・セカンド，サデイアス・エス
ガオ，イー
へイト，アンソニー・アール
ヘンジベルド，ジヨン・イー
ヘンリー，ロジヤー・エフ
コテツキー，ブライアン・ジエイ
ロウ，シヤオチユン
サリス，キヤシー
ジヤン，ジエフ・ジー・ゼツト
Original Assignee
アッヴィ・バハマズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5734654(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アッヴィ・バハマズ・リミテッド filed Critical アッヴィ・バハマズ・リミテッド
Publication of JP2010539186A publication Critical patent/JP2010539186A/ja
Publication of JP2010539186A5 publication Critical patent/JP2010539186A5/ja
Application granted granted Critical
Publication of JP5734654B2 publication Critical patent/JP5734654B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
JP2010525102A 2007-09-17 2008-09-17 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 Expired - Fee Related JP5734654B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US60/972,877 2007-09-17
US9679108P 2008-09-13 2008-09-13
US61/096,791 2008-09-13
PCT/US2008/076576 WO2009039127A1 (en) 2007-09-17 2008-09-17 Uracil or thymine derivative for treating hepatitis c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012225875A Division JP2013049681A (ja) 2007-09-17 2012-10-11 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体

Publications (3)

Publication Number Publication Date
JP2010539186A JP2010539186A (ja) 2010-12-16
JP2010539186A5 JP2010539186A5 (enExample) 2012-11-15
JP5734654B2 true JP5734654B2 (ja) 2015-06-17

Family

ID=39948002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010525102A Expired - Fee Related JP5734654B2 (ja) 2007-09-17 2008-09-17 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体
JP2012225875A Pending JP2013049681A (ja) 2007-09-17 2012-10-11 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012225875A Pending JP2013049681A (ja) 2007-09-17 2012-10-11 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体

Country Status (30)

Country Link
US (3) US8415351B2 (enExample)
EP (2) EP2725015A1 (enExample)
JP (2) JP5734654B2 (enExample)
KR (2) KR101552474B1 (enExample)
CN (2) CN101801935B (enExample)
AR (2) AR070027A1 (enExample)
AU (1) AU2008302448B2 (enExample)
BR (1) BRPI0816994B8 (enExample)
CA (2) CA2976793A1 (enExample)
CL (2) CL2008002794A1 (enExample)
CO (1) CO6260076A2 (enExample)
CR (2) CR11316A (enExample)
DO (2) DOP2010000084A (enExample)
ES (1) ES2453591T3 (enExample)
GT (1) GT201000061A (enExample)
IL (1) IL204547A (enExample)
IN (1) IN2012DN05113A (enExample)
MX (2) MX2010002905A (enExample)
MY (1) MY162760A (enExample)
NZ (3) NZ584720A (enExample)
PA (1) PA8796201A1 (enExample)
PE (2) PE20090705A1 (enExample)
PH (1) PH12013500365A1 (enExample)
RU (2) RU2543620C2 (enExample)
SG (1) SG183733A1 (enExample)
TW (2) TWI534137B (enExample)
UA (1) UA117800C2 (enExample)
UY (1) UY31344A1 (enExample)
WO (1) WO2009039127A1 (enExample)
ZA (2) ZA201204223B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918369B (zh) 2007-09-17 2016-02-24 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
PL2639226T3 (pl) 2007-09-17 2017-02-28 Abbvie Bahamas Ltd. Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
PA8796201A1 (es) 2007-09-17 2009-04-23 Abbott Lab Agentes anti-infecciosos y su uso
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
EP2307372B1 (en) 2008-07-23 2012-04-25 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
CN102164909A (zh) 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
NZ594923A (en) * 2009-03-24 2013-11-29 Abbott Lab Process for preparing antiviral compound
MX2011010047A (es) * 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.
JP2012522013A (ja) * 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
JP2012524752A (ja) 2009-04-25 2012-10-18 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
MX2011012541A (es) 2009-06-24 2012-08-03 Hoffmann La Roche Compuestos heterociclicos antivirales.
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
CA2768924A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102639504A (zh) * 2009-11-21 2012-08-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
CA2780526A1 (en) 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US9216952B2 (en) * 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
ES2481411T3 (es) 2010-07-07 2014-07-30 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
CA2805748A1 (en) 2010-07-16 2012-01-19 Shashank Shekhar Process for preparing n-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide
SG187103A1 (en) 2010-07-16 2013-02-28 Abbvie Inc Phosphine ligands for catalytic reactions
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
MX2013001273A (es) 2010-08-13 2013-04-10 Hoffmann La Roche Compuestos heterociclicos antivirales.
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
WO2012129099A1 (en) 2011-03-18 2012-09-27 Abbott Laboratories Formulations of phenyl uracil compounds
WO2012130941A2 (de) * 2011-03-31 2012-10-04 Schaefer Konstanze Perfluorierte verbindungen zum nicht-viralen transfer von nukleinsäuren
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
CN104024241B (zh) 2011-08-01 2016-01-20 大日本住友制药株式会社 尿嘧啶衍生物和其用于医学目的的用途
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PE20161416A1 (es) 2012-05-15 2017-01-08 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
CA2870339C (en) 2012-05-15 2020-06-02 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
EP2866807A2 (en) 2012-06-27 2015-05-06 Abbvie Inc. Methods for treating hcv
CA2882624A1 (en) * 2012-08-21 2014-02-27 Shashank Shekhar Process for preparing antiviral compounds
WO2014063101A1 (en) 2012-10-18 2014-04-24 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
US20150011481A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
BR112016000241B1 (pt) 2013-07-08 2021-06-22 Bayer Cropscience Aktiengesellschaft Compostos pesticidas derivados de sulfeto de arila e sulfóxido de arila, formulação, seus usos, método para controle de pragas e método de proteção de semente ou planta
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015116594A1 (en) 2014-01-28 2015-08-06 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
JP6759514B2 (ja) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
US20160074462A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Method of Treating HCV
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
CN108137514A (zh) * 2015-07-30 2018-06-08 百时美施贵宝公司 芳基取代的二环杂芳基化合物
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
EP0442473B1 (en) 1990-02-15 1998-08-19 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (enExample) 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
DE60034061T2 (de) 1999-12-06 2007-12-13 F. Hoffmann-La Roche Ag 4-pyrimidinyl-n-acyl-l-phenylanine
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
IL167958A (en) 2000-02-04 2010-11-30 Sumitomo Chemical Co 2-thio 3-hydroxypyridine derivatives
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
TW200505872A (en) * 2003-06-13 2005-02-16 Lg Life Science Ltd Hepatitis C virus inhibitors
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JO2934B1 (en) * 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
PA8796201A1 (es) * 2007-09-17 2009-04-23 Abbott Lab Agentes anti-infecciosos y su uso
PL2639226T3 (pl) 2007-09-17 2017-02-28 Abbvie Bahamas Ltd. Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
CN101918369B (zh) * 2007-09-17 2016-02-24 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
EP2307372B1 (en) 2008-07-23 2012-04-25 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
CA2699981C (en) 2017-08-22
CL2008002794A1 (es) 2009-09-04
US8685991B2 (en) 2014-04-01
NZ584720A (en) 2012-07-27
KR101552474B1 (ko) 2015-09-11
PE20090705A1 (es) 2009-07-17
ES2453591T3 (es) 2014-04-08
AR070027A1 (es) 2010-03-10
CA2976793A1 (en) 2009-03-26
RU2013104270A (ru) 2014-08-10
CR11316A (es) 2010-10-05
EP2725015A1 (en) 2014-04-30
MX2010002905A (es) 2010-07-05
TWI534137B (zh) 2016-05-21
PE20130209A1 (es) 2013-03-24
GT201000061A (es) 2012-03-26
WO2009039127A1 (en) 2009-03-26
KR20150117632A (ko) 2015-10-20
PA8796201A1 (es) 2009-04-23
CL2013000372A1 (es) 2013-10-04
PH12013500365A1 (en) 2014-09-08
TW200918066A (en) 2009-05-01
AU2008302448B2 (en) 2014-11-06
KR101660360B1 (ko) 2016-09-27
US20110070193A1 (en) 2011-03-24
CN102746239B (zh) 2016-02-10
BRPI0816994B8 (pt) 2021-05-25
CN101801935A (zh) 2010-08-11
RU2543620C2 (ru) 2015-03-10
CO6260076A2 (es) 2011-03-22
CA2699981A1 (en) 2009-03-26
BRPI0816994A2 (pt) 2015-03-24
UA117800C2 (uk) 2018-10-10
NZ600371A (en) 2014-07-25
US20140235638A1 (en) 2014-08-21
CN102746239A (zh) 2012-10-24
CR20150238A (es) 2015-07-01
SG183733A1 (en) 2012-09-27
MY162760A (en) 2017-07-14
AR087472A2 (es) 2014-03-26
AU2008302448A1 (en) 2009-03-26
CN101801935B (zh) 2014-12-03
IL204547A0 (en) 2010-11-30
IN2012DN05113A (enExample) 2015-10-23
DOP2010000396A (es) 2013-12-31
UY31344A1 (es) 2009-04-30
ZA201204224B (en) 2015-12-23
HK1147256A1 (en) 2011-08-05
JP2010539186A (ja) 2010-12-16
JP2013049681A (ja) 2013-03-14
DOP2010000084A (es) 2010-06-15
EP2222646A1 (en) 2010-09-01
MX338555B (es) 2016-04-20
US9095590B2 (en) 2015-08-04
EP2222646B1 (en) 2014-01-22
RU2010114828A (ru) 2011-10-27
ZA201204223B (en) 2015-12-23
BRPI0816994B1 (pt) 2019-12-24
NZ618277A (en) 2015-07-31
TWI437994B (zh) 2014-05-21
US8415351B2 (en) 2013-04-09
RU2599635C2 (ru) 2016-10-10
US20120213733A1 (en) 2012-08-23
KR20100068289A (ko) 2010-06-22
IL204547A (en) 2016-04-21
TW201443027A (zh) 2014-11-16

Similar Documents

Publication Publication Date Title
JP5734654B2 (ja) Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体
JP5734655B2 (ja) 抗感染症ピリミジンおよびその使用
JP5726527B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）阻害薬として有用なｎ−フェニル−ジオキソ−ヒドロピリミジン
AU2014280939B2 (en) Uracil or thymine derivative for treating hepatitis C
HK1189590B (en) Anti-infective pyrimidines and uses thereof
HK1156033B (en) Anti-infective pyrimidines and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140623

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150415

R150 Certificate of patent or registration of utility model

Ref document number: 5734654

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees